The company also saw increases in its international revenues and within its hospital group. Further notable is that the increase in the company's sleep therapy revenues was achieved during a quarter when it completed its planned transition to the new M-Series platform of positive airway pressure devices. "We completed the planned transition to our new family of sleep therapy products during our second quarter, and our M-series of devices is now fully launched," said John Miclot, president and CEO. "During the quarter our global sleep therapy revenues increased by approximately 16% year-over-year while we completed the transition to the M-Series." Looking Ahead In order to build on its success, Respironics is launching the My Life™ series of masks. OptiLife™, the first in the mask series, was designed to be the easiest-to-use interface for delivering positive airway therapy for the treatment of OSA.